AGIO earnings call for the period ending September 30, 2019.
News & Analysis: Agios Pharmaceuticals
It was a roller-coaster year for investors in the clinical-stage biotech. Here's a review of the year's key headlines that caused shares to drop.
The biotech is left without a backup plan.
The biotech is the big loser from the American Society of Hematology meeting.
The biotech's partner plans to submit an application for approval by the end of the year.
Drug safety and competitive concerns hold back Agios in the first half of 2016.
Agios released exciting news about a new collaboration agreement, sending shares higher in May.
Potential safety issues with one of the biotech's pipeline drugs worry investors.
Shareholders relish in Agios' 21% spike in April, but can the momentum continue?
Agios Pharmaceuticals actually delivered an encouraging strategic outline at the J.P. Morgan Healthcare Conference, but wound up being derailed by investor sentiment.